SCHEMBL4407545

SCHEMBL4407545

Cc1nsc2nc(-c3ccc(F)cc3)c(-c3ccnc(S(C)(=O)=O)n3)cc12

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.38
MITF O75030 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
STAT3 P40763 1/20 0.38
STAT1 P42224 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TLR9 Q9NR96 1/20 0.38
PTGS2 P35354 13/20 0.36
PTGS1 P23219 3/20 0.35
MAPK14 Q16539 2/20 0.34
MAPK13 O15264 1/20 0.34
MAPK12 P53778 1/20 0.34
MAPK11 Q15759 1/20 0.34
DYRK1B Q9Y463 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4409899 0.81 ALDH1A1 (0.40) KDM4EMITFALDH1A1LMNASTAT3
SCHEMBL4409134 0.81 MAPK14 (0.47) ALDH1A1LMNASMN1; SMN2MAPK14MAPK13
SCHEMBL4410198 0.80 PTGS2 (0.43) KDM4EMITFALDH1A1LMNASTAT3
SCHEMBL4412109 0.77 DYRK1A (0.39) KDM4EALDH1A1MAPK14MAPK13MAPK12
SCHEMBL4412103 0.75 MAP4K4 (0.49) MAPK14MAPK13MAPK12MAPK11
SCHEMBL4406273 0.74 MAPK13 (0.51) MAPK14MAPK13MAPK12MAPK11
SCHEMBL4406271 0.74 MAPK13 (0.51) MAPK14MAPK13MAPK12MAPK11
SCHEMBL4415915 0.74 MAPK14 (0.47) MAPK14MAPK13MAPK12MAPK11
SCHEMBL2410945 0.73 RAB9A (0.56) KDM4EMITFALDH1A1LMNASTAT3
SCHEMBL1384763 0.72 MAP4K4 (0.42) KDM4EMITFALDH1A1LMNASTAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2009-10-22 US disclosed
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2008-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors MAPK1, MAP4K2, MAP3K1 KDM4E 1486/4885MITF 2123/4885ALDH1A1 2298/4885
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors MAPK1, MAP4K2, MAP3K1 KDM4E 1486/4885MITF 2123/4885ALDH1A1 2298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.